Statins Do Double Duty Against Stroke

A new study suggests that inpatient statin use is linked to improved outcomes after intracranial hemorrhage. And 2 new studies suggest that a new class of injectable antihyperlipidemics, the PSK9 inhibitors--which have been shown to lower LDL-- may decrease cardiovascular events, including stroke.Details of those studies appear in the following slides. Take home points include:Inpatient statin use is linked to improved outcomes after ICH, and that stopping statins during hospitalization is associated with worse outcomes.PSK9 inhibitors are a new class of injectable antihyperlipidemics that have been shown to lower LDL and may also decrease risk of cardiovascular events, including strokeA study has suggested that evolocumab, a new PSK9 inhibitor, plus standard therapy reduces LDL by 61% and cardiovascular events by about half, compared to standard therapy aloneAnother study has suggested that  alirocumab, also a PSK9 inhibitor, reduces LDL by 62% and cardiovascular risk by about half, compared to placeboBoth PSK9 inhibitors were linked to increased rates of neurocognitive disorders